Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | HTRA1 | Q92743 | 2/20 | 0.32 |
| ▸ | ASIC1 | P78348 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19702814 | 0.91 | PTGDR2 (0.35) | PTGER4ALOX15L3MBTL1MEN1KMT2A | |
| SCHEMBL19702812 | 0.85 | PTGDR2 (0.35) | PTGER4L3MBTL1MEN1KMT2ARET | |
| SCHEMBL17777768 | 0.82 | PTGDR2 (0.36) | PTGER4ALOX15L3MBTL1BRD4KMT2A | |
| SCHEMBL20575340 | 0.80 | AKR1C3 (0.36) | AKR1C3HTRA1AKR1C2PTGER4BRD4 | |
| SCHEMBL17777810 | 0.79 | ASIC1 (0.36) | ASIC1BRD4MEN1KMT2A | |
| SCHEMBL17873350 | 0.77 | AAK1 (0.35) | — | |
| SCHEMBL17777930 | 0.72 | KCNK3 (0.38) | ASIC1MEN1KMT2A | |
| SCHEMBL19702820 | 0.72 | PTGDR2 (0.41) | ALOX15L3MBTL1MEN1KMT2A | |
| SCHEMBL19702813 | 0.72 | PTGDR2 (0.41) | ALOX15L3MBTL1MEN1KMT2A | |
| SCHEMBL19659387 | 0.71 | CYP2D6 (0.34) | AKR1C3AKR1C2PTGER4L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200407364-A1 | FUSED BICYCLIC COMPOUNDS | AKARNA THERAPEUTICS LTD (GB) | 2020-12-31 | — | — | US | disclosed |
| US-20180346473-A1 | FUSED BICYCLIC COMPOUNDS | AKARNA THERAPEUTICS, LTD. (TW) | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346473-A1 | FUSED BICYCLIC COMPOUNDS | BICRA, PAICS, NDC1 | AKR1C3 2360/4885HTRA1 4564/4885ASIC1 4693/4885 |
| US-20200407364-A1 | FUSED BICYCLIC COMPOUNDS | BICRA, PAICS, NDC1 | AKR1C3 2360/4885HTRA1 4564/4885ASIC1 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.